• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#Visual Abstract: Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

byStudy Graphics | C.WuandConstance Wu
August 22, 2020
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

RELATED REPORTS

#VisualAbstract: Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab treatment does not show added activity in chronic lymphocytic leukaemia

#VisualAbstract Obinutuzumab plus lenalidomide is an active and safe therapy in advanced, previously untreated follicular lymphoma

#VisualAbstract Acalabrutinib monotherapy has acceptable tolerability and limited response in patients with Richter transformation

1. In untreated chronic lymphocytic leukemia (CLL) patients with coexisting conditions, patients treated with venetoclax–obinutuzumab experienced greater progression-free survival compared to patients treated with chlorambucil–obinutuzumab.

2. Rates of adverse events in the two treatment groups were similar.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Many patients with CLL are elderly and have clinically relevant comorbid health conditions. The BCL2 antiapoptotic protein is overexpressed in CLL, and venetoclax is an oral BCL2 homology domain 3 mimetic compound which aids to induce apoptosis in B-cells. Whether venetoclax can improve treatment efficacy in CLL patients with comorbidities while limiting toxicity is undetermined. This open-label, phase 3 trial showed progression-free survival is significantly increased in patients taking venetoclax as part of their treatment regimen. Adverse outcomes compared to the current standard treatment regimen were similar.

This study supports the use of venetoclax in CLL patients with comorbidities as it optimizes a key survival outcome while toxicity is comparable with the current treatment standard. The study is limited in its strength to detect a difference in overall survival.

Click to read the study in NEJM

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: BCL2chlorambucilchronic lymphocytic leukemia (CLL)Obinutuzumabvenetoclax
Previous Post

Alzheimer’s Disease imaging biomarkers slightly improve prediction of memory decline

Next Post

Quick Take: Evaluating the impact of community health volunteer home visits on child diarrhea and fever in the Volta Region, Ghana

RelatedReports

#VisualAbstract: Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab treatment does not show added activity in chronic lymphocytic leukaemia
StudyGraphics

#VisualAbstract: Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab treatment does not show added activity in chronic lymphocytic leukaemia

March 24, 2022
#VisualAbstract Obinutuzumab plus lenalidomide is an active and safe therapy in advanced, previously untreated follicular lymphoma
StudyGraphics

#VisualAbstract Obinutuzumab plus lenalidomide is an active and safe therapy in advanced, previously untreated follicular lymphoma

December 31, 2021
#VisualAbstract Acalabrutinib monotherapy has acceptable tolerability and limited response in patients with Richter transformation
StudyGraphics

#VisualAbstract Acalabrutinib monotherapy has acceptable tolerability and limited response in patients with Richter transformation

November 11, 2021
#VisualAbstract Venetoclax with dose-adjusted EPOCH-R may be a promising combination therapy for aggressive B-cell lymphoma
StudyGraphics

#VisualAbstract Venetoclax with dose-adjusted EPOCH-R may be a promising combination therapy for aggressive B-cell lymphoma

October 21, 2021
Next Post
Quick Take: Evaluating the impact of community health volunteer home visits on child diarrhea and fever in the Volta Region, Ghana

Quick Take: Evaluating the impact of community health volunteer home visits on child diarrhea and fever in the Volta Region, Ghana

#VisualAbstract: Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa

#VisualAbstract: Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa

UTI associated with increased risk of preeclampsia

The CREOLE trial: amlodipine and either hydrochlorothiazide or perindopril optimally lowers blood pressure in black African patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options